Neuroactive steroids for the treatment of Huntington's disease

Administering Compound 1 to subjects with Huntington's disease-related mild cognitive impairment improves cognitive functions by targeting executive function and working memory, addressing the need for therapeutic agents in this condition.

JP2024544777AInactive Publication Date: 2024-12-04SAGE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024535430
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-08
Filing Date
2022-12-12
Publication Date
2024-12-04
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for therapeutic agents to treat mild cognitive impairment associated with Huntington's disease, which is common and associated with decreased quality of life and a high risk of developing dementia.

Method used

Administering a compound, referred to as Compound 1, or its pharmaceutically acceptable salt, to subjects with mild cognitive impairment due to Huntington's disease, at doses ranging from 0.3 to 6 mg/day, to improve cognitive functions such as executive function, working memory, and learning.

Benefits of technology

Compound 1 effectively improves cognitive functions in subjects with mild cognitive impairment associated with Huntington's disease, enhancing executive function, working memory, and learning.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544777000001_ABST
    Figure 2024544777000001_ABST
Patent Text Reader

Abstract

Provided herein is a method for improving working memory and / or executive function in a subject suffering from Huntington's disease, the method comprising administering to the subject SAGE-718, an investigational positive allosteric modulator of the NMDA receptor.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 289,081, filed December 13, 2021, No. 63 / 321,598, filed March 18, 2022, and No. 63 / 404,678, filed September 8, 2022. The disclosures of each of the foregoing applications are incorporated herein by reference in their entirety. [Background technology]

[0002] Mild cognitive impairment is common in patients with Huntington's disease (HD) and is associated with reduced quality of life and functional impairment. Moreover, patients with HD-mild cognitive impairment (HD-MCI) are at increased risk of developing dementia.

[0003] NMDA receptors are highly expressed in the CNS and are involved in excitatory synaptic transmission. Activation of these receptors contributes to synaptic plasticity in some circumstances and to excitotoxicity in others. These receptors mediate Ca release following binding of the neurotransmitters glutamate and glycine. 2+ NMDA receptors are ligand-gated ion channels that accept NMDA receptors and are essential for excitatory neurotransmission and normal CNS function. NMDA receptors are heteromeric complexes composed of NR1, NR2, and / or NR3 subunits and have distinct recognition sites for exogenous and endogenous ligands. These recognition sites include binding sites for glycine, as well as glutamatergic agonists and modulators. Positive modulators may be useful as therapeutic agents with potential clinical applications as nootropics and in the treatment of psychiatric disorders in which glutamatergic transmission is reduced or absent (see, e.g., Horak et al., J.Neuroscience, 2004, 24(46), 10318-10325). In contrast, negative modulators may be useful as therapeutic agents with potential clinical applications in the treatment of psychiatric disorders in which glutamatergic transmission is pathologically increased (e.g., treatment-resistant depression). There remains a need for therapeutic agents to treat mild cognitive impairment associated with Huntington's disease. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Horak et al.,J.Neuroscience,2004,24(46),10318-10325 Summary of the Invention

[0005] A method of treating mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to a subject a compound having the formula: [ka] or a pharma- ceutically acceptable salt thereof.

[0006] In a first aspect, provided herein is a method of treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, the method comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.

[0007] In a second aspect, provided herein is a method of improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease in the subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.

[0008] In a third aspect, provided herein is a method of improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease in the subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.

[0009] In a fourth aspect, provided herein is a method of improving learning in a subject having mild cognitive impairment (MCI) associated with Huntington's disease in the subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.

[0010] In a fifth aspect, provided herein is a method of improving learning and working memory in a subject having MCI associated with Huntington's disease in the subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.

[0011] In some embodiments, the subject is an adult human. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered as monotherapy. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered in combination with another therapeutic agent. [Brief description of the drawings]

[0012] [Figure 1]Figure 1 shows the LS mean change from baseline in the TWOB test by time point in HD patients. Higher scores = better performance in the TWOB test. [Diagram 2] Figure 1 shows the LS mean change from baseline in the GML test by time point in HD patients. Lower scores = better performance in the GML test. [Diagram 3] 1 shows performance measured using a 2-back test in patients with Huntington's disease and healthy participants. Z-transformed change (mean±SEM) from baseline to day 14 is shown. [Figure 4] 1 shows performance measured using the Groton Maze Learning Test in patients with Huntington's Disease and healthy participants. Z-transformed change (mean±SEM) from baseline to day 14 is shown. [Diagram 5] 1 shows performance measured using a psychomotor vigilance task test in patients with Huntington's disease and healthy participants. Z-transformed change (mean±SEM) from baseline to day 14 is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] As generally described herein, the present invention provides compounds and compositions useful for improving cognitive function in a subject in need thereof.

[0014] definition The term "herein" means the entire application.

[0015] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the terminology used in connection with the compounds, compositions and methods described herein are those well known and commonly used in the art.

[0016] It is to be understood that any of the embodiments described herein, including those described in different aspects of the disclosure and under different parts of this specification (including those described in the examples only), can be combined with any one or more other embodiments of the invention, unless expressly disclaimed or inappropriate, and that combinations of embodiments are not limited to those specific combinations claimed via the scope of the multiple dependent claims.

[0017] All publications, patents and published patent applications mentioned in this application are specifically incorporated herein by reference. In case of conflict, the present specification, including its specific definitions, will control.

[0018] Throughout this specification, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer (element or component) or group of integers (elements or components) but not the exclusion of any other integer (element or component) or group of integers (elements or components).

[0019] Throughout this specification, when a composition is described as having, including, or comprising certain components (or variations thereof), it is contemplated that the composition may also consist essentially of or consist of the recited components. Similarly, when a method or process is described as having, including, or comprising certain process steps, the process may also consist essentially of or consist of the recited processing steps. Furthermore, it is to be understood that the order of steps or the order of performing certain actions is not important so long as the compositions and methods described herein remain operable. Moreover, two or more steps or actions may be performed simultaneously.

[0020] The term "including" as used herein means "including, but not limited to." "Including" and "including, but not limited to" are used interchangeably. Thus, it will be understood that these terms imply the inclusion of a stated integer (element or component) or group of integers (elements or components) but not the exclusion of any other integer (element or component) or group of integers (elements or components).

[0021] As used herein, the term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend, in part, on how the value is measured or determined, i.e., the limitations of the measurement system.

[0022] Unless otherwise required by context, singular terms shall include plurals and plural terms shall include the singular.

[0023] The use of the terms "a," "an," and "the" and similar referents in the context of describing elements (particularly in the context of the claims which follow) are to be construed to encompass both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0024] As used herein, the term "or" should be understood to mean "and / or" unless the context clearly dictates otherwise.

[0025] The recitation of ranges of values ​​herein is intended to serve merely as a shorthand method of individually referring to each separate value within the range, unless otherwise indicated herein, and each separate value is incorporated herein as if it were individually listed herein. Moreover, all ranges disclosed herein should be understood to encompass any and all subranges contained therein. For example, a range stated as "1-10" should be considered to include any and all subranges between a minimum value of 1 and a maximum value of 10 (inclusive), i.e., all subranges beginning with a minimum value of 1 or more, e.g., 1-6.1, and ending with a maximum value of 10 or less, e.g., 5.5-10. The disclosure of a range should also be considered as the disclosure of the endpoints of that range.

[0026] All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context.

[0027] The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended merely to better describe the embodiments and does not limit the scope of the claims unless expressly stated otherwise. No language in the specification should be construed as indicating any non-claimed element as essential.

[0028] "Pharmaceutically acceptable" means approved or capable of being approved by a regulatory agency of the Federal government, a state government, or a corresponding agency in a country other than the United States, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, and more specifically, in humans.

[0029] "Pharmaceutically acceptable salt" refers to a salt of the compound of the present invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoic acid)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, Included are acid addition salts formed with organic acids such as 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylbutyric acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, or (2) salts formed where an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion, or equivalent with an organic base, such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc., and where the compound contains a basic functional group, salts of non-toxic organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, etc. The term "pharmacologically acceptable cation" refers to an acceptable cationic counterion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like. See, e.g., Berge, et al., J. Pharm. Sci. (1977) 66(1):1-79.

[0030] As used herein, the term "unit dosage form" is defined to refer to the form in which a compound disclosed herein (eg, Compound 1) is administered to a subject.

[0031] As used herein, the term "daily" means a given contiguous 24-hour period.

[0032] The terms "subject" and "patient" are used interchangeably herein and include, but are not limited to, humans and non-human animals, e.g., mammals such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cows, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is a human ("human subject"). In certain embodiments, the human subject is an infant, child, or adolescent ("pediatric subject"). In other embodiments, the human subject is a young adult, middle-aged adult, or elderly adult ("adult subject"). In certain embodiments, the subject is a non-human animal ("non-human subject").

[0033] As used herein, and unless otherwise specified, the terms "treat," "treating," and "treatment" contemplate the act of reducing the severity of, or slowing down the progression of, a specified disease, disorder, or condition (also referred to as "therapeutic treatment"), which occurs while a subject is afflicted with the specified disease, disorder, or condition.

[0034] In general, the "effective amount" of a compound refers to an amount sufficient to induce a desired biological response.As will be understood by those skilled in the art, the effective amount of the compound of the present disclosure can vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease to be treated, the mode of administration, and the age, weight, health and condition of the subject.

[0035] As used herein, and unless otherwise specified, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, delay or minimize one or more symptoms associated with a disease, disorder, or condition, or improve cognitive function. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent that alone or in combination with other therapies provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" can include an amount that improves overall therapy, reduces or avoids the symptoms or causes of a disease or condition, or enhances the therapeutic effectiveness of another therapeutic agent.

[0036] In some embodiments, administering a compound described herein or a pharma- ceutically acceptable salt thereof improves cognitive function. In some embodiments, cognitive function refers to a set of mental tasks and functions, including, but not limited to, psychomotor performance, executive performance, emotion recognition, learning (e.g., visual, spatial), memory (e.g., semantic, episodic, procedural, priming, or task), orientation, language, problem solving, visual perception, organization, and integration, planning, organizational skills, selective attention, inhibitory control, and the ability to mentally manipulate information. In some embodiments, cognitive function is one or more selected from the group consisting of psychomotor performance, executive performance, emotion recognition, learning (e.g., visual, spatial), memory (e.g., semantic, episodic, procedural, priming, or task), orientation, language, problem solving, visual perception, organization, and integration, planning, organizational skills, selective attention, inhibitory control, and the ability to mentally manipulate information. In some embodiments, compound 1 selectively targets working memory and its improvement. In some embodiments, compound 1 selectively targets executive performance and its improvement. Measures of cognitive function include, for example, assessment tools designed to measure (a) general intelligence, (b) non-verbal intelligence, (c) achievement, (d) attention / executive function, (e) memory and learning, (f) visual-motor and motor function, and (g) language.

[0037] For example, any change in cognitive function over time or during the course of treatment can be monitored by using one or more of these well-established tests at two or more time points and comparing the results.The phrase "improve cognitive function" referred to herein refers to a favorable change in the subject's ability to perform symbolic operations, for example, to perceive, remember, create mental images, have clarity of thought, be aware, reason, think, or judge.The favorable change can be measured using any of the aforementioned tests on two or more occasions, for example, a first occasion to measure baseline cognitive function and a second occasion to measure cognitive function after a period of time (when treatment may have been administered).Such assessment tools are well known in the art and include, for example, the assessment tool described in Example 1 herein.

[0038] As used herein, the term "memory" is defined as the biological processes of the brain that enable the storage and recall of information.

[0039] As used herein, the term "working memory" is defined as the combination of brain processes that provide the temporary storage and manipulation of information necessary to perform complex cognitive tasks such as learning and reasoning.

[0040] As used herein, the term "learning" refers to the brain processes involved in the acquisition of skills, knowledge, and information.

[0041] The terms "executive function" or "executive performance," as used interchangeably herein, refer to an umbrella term for the cognitive processes that regulate, control, and manage other cognitive processes, including planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, task switching, and initiating and monitoring behavior. The prefrontal cortex of the frontal lobe is necessary, but not sufficient, to perform these functions.

[0042] "Improve," "improving," or "improvement," or grammatical variations thereof, when used in connection with working memory or executive function, refers to the ability to achieve a measurable increase in performance related to a task used to test working memory or executive function in a subject.

[0043] Pharmaceutical Compositions In one aspect, the disclosure provides a pharmaceutical composition comprising a compound of the invention (also referred to as an "active ingredient"), e.g., Compound 1 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises an effective amount of the active ingredient. In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the active ingredient. In certain embodiments, the pharmaceutical composition comprises a prophylactically effective amount of the active ingredient.

[0044] The pharmaceutical compositions provided herein may be administered by a variety of routes, including, but not limited to, oral (enteral), parenteral (by injection), rectal, transdermal, intradermal, intrathecal, subcutaneous (SC), intravenous (IV), intramuscular (IM), and intranasal administration. In some embodiments, the compound or pharmaceutical composition is administered to the subject orally. In some embodiments, the compound or pharmaceutical composition is administered to the subject parenterally. In some embodiments, the compound or pharmaceutical composition is administered to the subject rectally. In some embodiments, the compound or pharmaceutical composition is administered to the subject transdermally. In some embodiments, the compound or pharmaceutical composition is administered to the subject intradermally. In some embodiments, the compound or pharmaceutical composition is administered to the subject intrathecally. In some embodiments, the compound or pharmaceutical composition is administered to the subject subcutaneously. In some embodiments, the compound or pharmaceutical composition is administered to the subject intravenously. In some embodiments, the compound or pharmaceutical composition is administered to the subject intramuscularly. In some embodiments, the compound or pharmaceutical composition is administered to the subject intranasally.

[0045] In general, the compounds provided herein are administered in an effective amount. The amount of compound actually administered is typically determined by a physician in light of the relevant circumstances, including the condition being treated, the selected route of administration, the compound actually administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0046] In some embodiments, the pharmaceutical composition comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the pharmaceutical composition comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the pharmaceutical composition comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises about 0.5 mg of Compound 1. In some embodiments, the pharmaceutical composition comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1.

[0047] In some embodiments, the pharmaceutical composition comprises 0.1-1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises 0.1-1.0 mg of Compound 1. In some embodiments, the pharmaceutical composition comprises 0.1-1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the pharmaceutical composition comprises 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises 0.5 mg of Compound 1. In some embodiments, the pharmaceutical composition comprises 0.5 mg of Compound 1. In some embodiments, the pharmaceutical composition comprises 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the pharmaceutical composition comprises 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises 1.0 mg of Compound 1. In some embodiments, the pharmaceutical composition comprises 1.0 mg of Compound 1.

[0048] The pharmaceutical composition of the present invention can further be delivered using various dosing methods. For example, in certain embodiments, the pharmaceutical composition can be given as a bolus, for example, to raise the concentration of the compound in the blood to an effective level. The placement of the bolus dose depends on the systemic level of the active ingredient desired throughout the body, for example, an intramuscular or subcutaneous bolus dose allows for a slow release of the active ingredient, while a bolus delivered directly into a vein (e.g., via an IV drip) allows for a much faster delivery that quickly raises the concentration of the active ingredient in the blood to an effective level. In other embodiments, the pharmaceutical composition can be administered as a continuous infusion, for example, by IV drip, to provide maintenance of a steady-state concentration of the active ingredient in the subject's body. Furthermore, in still other embodiments, the pharmaceutical composition can be initially administered as a bolus dose, followed by a continuous infusion.

[0049] Compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage form" refers to physically discrete units suitable as unit dosages for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce a desired therapeutic effect, together with suitable pharmaceutical excipients. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of liquid compositions, or pills, tablets, capsules, and the like, in the case of solid compositions. In such compositions, the compound is usually a minor component (about 0.1 to about 50% by weight, preferably about 1 to about 40% by weight), with the remainder being various vehicles or excipients and processing aids that serve to form the desired dosage form.

[0050] The above-mentioned components of the orally administrable, injectable, or topically administrable compositions are merely representative. Other materials, processing techniques, and the like are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[0051] The compounds of the invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0052] The present invention also relates to pharma- ceutically acceptable acid addition salts of the compounds of the present invention. Acids that can be used to prepare pharma- ceutically acceptable salts are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, paratoluenesulfonate, etc.

[0053] When used to prevent the development of a CNS disorder, the compounds provided herein will be administered at dosage levels described herein, typically under the advice and supervision of a physician, to subjects at risk of developing the condition. Subjects at risk of developing a particular condition generally include subjects with a family history of the condition, or subjects identified by genetic testing or screening as being particularly susceptible to developing the condition.

[0054] Treatment Methods and Uses A method of treating mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to a subject a compound having the formula: [ka] or a pharma- ceutically acceptable salt thereof.

[0055] Thus, in one aspect, provided herein is a method of treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0056] In another aspect, provided herein is a method of treating mild cognitive impairment (MCI) due to Huntington's disease in a subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of treating mild cognitive impairment (MCI) due to Huntington's disease in a subject, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of treating mild cognitive impairment (MCI) due to Huntington's disease in a subject, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0057] In another aspect, provided herein is a method of treating mild cognitive impairment (MCI) in a subject with Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of treating mild cognitive impairment (MCI) in a subject with Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of treating mild cognitive impairment (MCI) in a subject with Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0058] In one aspect, provided herein is a method of improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0059] In another aspect, provided herein is a method of improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3 to 6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0060] In another aspect, provided herein is a method of improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0061] In one aspect, provided herein is a method of improving working memory in a subject having MCI associated with Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease in a subject, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease in a subject, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0062] In another aspect, provided herein is a method of improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0063] In another aspect, provided herein is a method of improving working memory in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving working memory in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving working memory in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0064] In one aspect, provided herein is a method of improving learning in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving learning in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving learning in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0065] In another aspect, provided herein is a method of improving learning in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving learning in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving learning in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0066] In another aspect, provided herein is a method of improving learning in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving learning in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving learning in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0067] In one aspect, provided herein is a method of improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0068] In another aspect, provided herein is a method of improving learning and working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving learning and working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving learning and working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease, comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally.In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0069] In another aspect, provided herein is a method of improving learning and working memory in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, provided herein is a method of improving learning and working memory in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject Compound 1. In some embodiments, provided herein is a method of improving learning and working memory in a Huntington's disease subject with mild cognitive impairment (MCI), comprising administering to the subject a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is administered to the subject daily. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to the subject daily. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is administered to the subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered to the subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is administered orally. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is administered orally.

[0070] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1 to 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is for oral administration.

[0071] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for treating mild cognitive impairment (MCI) due to Huntington's disease in a subject. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for treating mild cognitive impairment (MCI) due to Huntington's disease in a subject. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for treating mild cognitive impairment (MCI) due to Huntington's disease in a subject. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1 to 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is for oral administration.

[0072] In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for treating mild cognitive impairment (MCI) in a subject with Huntington's disease. In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for treating mild cognitive impairment (MCI) in a subject with Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1, for the manufacture of a medicament for treating mild cognitive impairment (MCI) in a subject with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1 to 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is for oral administration.

[0073] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0074] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0075] In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1, for the manufacture of a medicament for improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1 to 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharmaceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharmaceutically acceptable salt of Compound 1 is for oral administration.

[0076] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0077] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for a method of improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for a method of improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 0.1 to about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 0.5 mg of Compound 1. In some embodiments, the medicament comprises about 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of Compound 1. In some embodiments, the medicament comprises about 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.1-1.0 mg of Compound 1. In some embodiments, the medicament comprises 0.1-1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of Compound 1. In some embodiments, the medicament comprises 0.5 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, the medicament comprises 1.0 mg of Compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, the medicament comprises 1.0 mg of Compound 1. In some embodiments, the medicament comprises 1.0 mg of a pharma- ceutically acceptable salt of Compound 1. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0078] In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving working memory in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving working memory in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1, for the manufacture of a medicament for improving working memory in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0079] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving learning in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for improving learning in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for improving learning in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0080] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving learning in a subject with mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for improving learning in a subject with mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for improving learning in a subject with mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0081] In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving learning in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving learning in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1, for the manufacture of a medicament for improving learning in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0082] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0083] In some embodiments, provided herein is the use of Compound 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of Compound 1 for the manufacture of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1 for the manufacture of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3 to 6 mg / day. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0084] In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving learning and working memory in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for improving learning and working memory in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is the use of a pharma- ceutically acceptable salt of Compound 1, for the manufacture of a medicament for improving learning and working memory in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0085] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. In some embodiments, provided herein is Compound 1 for use in treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0086] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in treating mild cognitive impairment (MCI) due to Huntington's disease in a subject. In some embodiments, provided herein is Compound 1 for use in treating mild cognitive impairment (MCI) due to Huntington's disease in a subject. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in treating mild cognitive impairment (MCI) due to Huntington's disease in a subject. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0087] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in treating a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is Compound 1 for use in treating a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in treating a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0088] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is Compound 1 for use in improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving executive function in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0089] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is Compound 1 for use in improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving executive function in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0090] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is Compound 1 for use in improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving executive function in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0091] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is Compound 1 for use in improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving working memory in a subject having mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0092] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is Compound 1 for use in improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving working memory in a subject having mild cognitive impairment (MCI) due to Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0093] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving working memory in Huntington's disease subjects with mild cognitive impairment (MCI). In some embodiments, provided herein is Compound 1 for use in improving working memory in Huntington's disease subjects with mild cognitive impairment (MCI). In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving working memory in Huntington's disease subjects with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0094] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is Compound 1 for use in improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0095] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving learning in a subject with Mild Cognitive Impairment (MCI) due to Huntington's Disease. In some embodiments, provided herein is Compound 1 for use in improving learning in a subject with Mild Cognitive Impairment (MCI) due to Huntington's Disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving learning in a subject with Mild Cognitive Impairment (MCI) due to Huntington's Disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0096] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving learning in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is Compound 1 for use in improving learning in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving learning in a Huntington's disease subject with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0097] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is Compound 1 for use in improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0098] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving learning and working memory in a subject with Mild Cognitive Impairment (MCI) due to Huntington's Disease. In some embodiments, provided herein is Compound 1 for use in improving learning and working memory in a subject with Mild Cognitive Impairment (MCI) due to Huntington's Disease. In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving learning and working memory in a subject with Mild Cognitive Impairment (MCI) due to Huntington's Disease. In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for oral administration. In some embodiments, the pharma- ceutically acceptable salt of Compound 1 is for oral administration.

[0099] In some embodiments, provided herein is Compound 1 or a pharma- ceutically acceptable salt thereof for use in improving learning and working memory in Huntington's disease subjects with mild cognitive impairment (MCI). In some embodiments, provided herein is Compound 1 for use in improving learning and working memory in Huntington's disease subjects with mild cognitive impairment (MCI). In some embodiments, provided herein is a pharma- ceutically acceptable salt of Compound 1 for use in improving learning and working memory in Huntington's disease subjects with mild cognitive impairment (MCI). In some embodiments, Compound 1 is for daily administration to a subject. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for daily administration to a subject. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of about 3 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 0.3-6 mg / day. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is for administration to a subject at a dose of 3 mg / day. In some embodiments, Compound 1 is for administration to a subject at a dose of 3 mg / day. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for administration to a subject at a dose of 3 mg / day.In some embodiments, Compound 1 is for oral administration. In some embodiments, a pharma- ceutically acceptable salt of Compound 1 is for oral administration. EXAMPLES

[0100] In order that the invention described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described in this application are provided to illustrate the compounds, pharmaceutical compositions, and methods provided herein, and are not to be construed in any way as limiting the scope thereof.

[0101] Example 1: Effect of Compound 1 on mild cognitive impairment caused by Huntington's disease The safety and tolerability of multiple ascending doses (MAD) of Compound 1 oral solution in healthy adults and subjects with early manifest Huntington's disease was evaluated in a dual-binding, placebo-controlled, Phase 1 MAD study.

[0102] Subjects were assigned sequentially to one of three cohorts. Part A of the study consisted of Cohort 1 and Cohort 2, each of which included approximately 12 healthy subjects, with 9 subjects receiving Compound 1 oral solution (0.5 mg or 1.0 mg) and 3 subjects receiving placebo. Sentinel dosing of 3 subjects was used 2:1 in Cohort 1 and Cohort 2, with 2 subjects randomized to receive Compound 1 oral solution and 1 subject randomized to receive placebo. The remaining 9 subjects were randomized 7:2 to receive Compound 1 oral solution or placebo. Cohort 1 and Cohort 2 were divided into 4 subgroups of 3 subjects. Each subgroup in Part A began dosing on Day 1 for 4 consecutive days, with the remaining dosing days staggered and overlapping. Treatment of up to 3 Part A subjects per calendar day per study site will begin on Day 1.

[0103] Part B of the study consisted of Cohort 3, which included approximately 10 subjects with early manifest Huntington's disease, all of whom received Compound 1 oral solution. Sentinel dosing of subjects was used in Cohort 3.

[0104] The screening period began with the signing of an informed consent form (ICF) at the screening visit. An optional genetic sample was taken during screening. Eligible subjects were admitted to the hospital on day -2 (Part A) or day -1 (Part B). Subjects were discharged on day 17 after all assessments were completed if the investigator was satisfied that it was safe to discharge the subject. In total, Part A subjects were hospitalized for approximately 19 days and Part B subjects were hospitalized for approximately 18 days. Subjects returned for a follow-up visit on day 21 (± 2 days), approximately 1 week after the end of treatment.

[0105] Six HD subjects were treated with Compound 1 and completed the study.

[0106] The primary objective of this study was to evaluate the safety and tolerability of Compound 1 oral solution as assessed by the incidence of adverse events (AEs) / serious adverse events (SAEs) and changes from baseline in vital signs, electrocardiogram (ECG), clinical laboratory parameters, and the Columbia-Suicide Severity Rating Scale (C-SSRS).

[0107] A secondary objective of this study was to evaluate the PK profile of Compound 1 following administration of multiple doses of Compound 1 oral solution (area under the curve [AUC], maximum observed concentration [C max ], C max The occurrence time [t max ] etc.).

[0108] Additional objectives included assessment of changes in subjects' performance on cognitive tasks.

[0109] Cognitive functions such as attention, working memory, information processing speed, executive function, and motor skills were assessed using the CogState battery, which consists of the Stop Signal Test (STOP), Detection Task (DET), Identification Task (IDN), One-Back Learning Task (ONB), Two-Back Learning Task (TWOB), and Groton Maze Learning Test (GML). Table 1. [Table 1-1] [Table 1-2]

[0110] The outcome measure for each CogState battery test was the change from baseline score at each post-baseline assessment time point.

[0111] Mean changes from baseline scores at all post-baseline assessment time points were analyzed using a mixed-effects repeated measures model (MMRM) with dose, visit, and the interaction between dose and visit as fixed effects, baseline as a covariate effect, and subject as a random effect. Unstructured covariance structures were used to model the variance-covariance matrix of repeated measures. When estimation problems arose during construction of the covariance structure, compound symmetry was used instead of unstructuring. Least squares (LS) means estimated with 95% confidence intervals between dose groups and placebo at each post-baseline time point.

[0112] Effect size, the magnitude of the difference between Compound 1 dose groups and placebo, was also assessed using Cohen's d (Cohen, 1988) using the following formula: Cohen's d score = (experimental group mean - control group mean) / pooled standard deviation (SD) of all samples.

[0113] Effect size: The size of the difference between the treatment group and placebo: less than 0.2 was considered trivial, 0.2 to 0.5 was considered small, 0.5 to 0.8 was considered medium, 0.8 to 1.1 was considered large, and greater than 1.1 was considered very large.

[0114] result Safety Overview: No deaths were reported No serious adverse events were reported No TEAEs leading to study or treatment discontinuation were reported. No TEAEs were reported in Part B in subjects with HD. There was no signal of an increase in suicidal ideation or behavior compared to baseline as measured by the C-SSRS.

[0115] Changes in HD subjects' performance in cognitive tasks Patients with HD who received Compound 1 (1 mg) exhibited improvements from baseline in executive function tests (see below and Figures 1-4). No changes from baseline were observed in psychomotor speed assessments (see Figure 5).

[0116] A.2 Backtesting HD subjects (Part B) demonstrated improved performance on the 2-back test following treatment with Compound 1 (1 mg) at all post-baseline time points, meeting the threshold for significant improvement (p<0.05) compared to baseline on days 8 to 14. LS mean changes from baseline on the 2-back (TWOB) test by time point are shown in Figures 1 and 3.

[0117] B. Groton Maze Learning (GML) Test: HD subjects (Part B) showed improvement in the GML test after treatment with Compound 1 (1 mg) at all time points except day 4. The mean change from baseline in the GML test by time point is shown in Figures 2 and 4.

[0118] C. Huntington's Disease Subject Baseline Cognitive Testing: HD subjects had worse baseline cognitive performance compared to healthy subjects, meeting the statistical significance threshold (p<0.05) for the 1-back test, 2-back test, and stop-signal test. Table 2 shows the comparison of baseline cognitive test results between HD and healthy subjects. [Table 2]

[0119] equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the compounds, compositions, and methods described herein which equivalents are considered to be within the scope of the invention.

[0120] Numbered embodiments Certain embodiments of the present disclosure are described in the following numbered paragraphs. 1. A method of treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, comprising administering to the subject a compound having the formula: [ka] or a pharma- ceutically acceptable salt thereof. 2. The method of embodiment 1, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject daily. 3. The method of embodiment 1 or 2, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 4. The method of embodiment 3, wherein about 3 mg of Compound 1 is administered to the subject per day. 5. The method of any one of embodiments 1-4, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 6. A method of improving executive function in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the following formula: [ka] or a pharma- ceutically acceptable salt thereof. 7. The method of embodiment 6, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject daily. 8. The method of embodiment 6 or 7, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 9. The method of embodiment 8, wherein about 3 mg of Compound 1 is administered to the subject per day. 10. The method of any one of embodiments 6-9, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 11. A method of improving working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the following formula: [ka] or a pharma- ceutically acceptable salt thereof. 12. The method of embodiment 11, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject daily. 13. The method of embodiment 11 or 12, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 14. The method of embodiment 13, wherein about 3 mg of Compound 1 is administered to the subject per day. 15. The method of any one of embodiments 11-14, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 16. A method of improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the following formula: [ka] or a pharma- ceutically acceptable salt thereof. 17. The method of embodiment 16, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject daily. 18. The method of embodiment 16 or 17, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 19. The method of embodiment 18, wherein about 3 mg of compound 1 is administered to the subject per day. 20. The method of any one of embodiments 16-19, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 21. A method of improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the following formula: [ka] or a pharma- ceutically acceptable salt thereof. 22. The method of embodiment 21, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject daily. 23. The method of embodiment 21 or 22, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 24. The method of embodiment 23, wherein about 3 mg of compound 1 is administered to the subject per day. 25. The method of any one of embodiments 21-24, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 26. The method of any one of embodiments 1-25, wherein the subject is an adult. 27. A compound having the following formula for use in treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject: [ka] or a pharma- ceutically acceptable salt thereof. 28. The compound for use according to embodiment 27, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered daily to the subject. 29. The compound for use according to embodiment 27 or 28, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 30. The compound for use according to embodiment 29, wherein about 3 mg of compound 1 is administered to the subject per day. 31. The compound for use according to any one of embodiments 27 to 30, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 32. A compound having the following formula for use in improving executive function in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 33. The compound for use according to embodiment 32, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered daily to the subject. 34. The compound for use according to embodiment 32 or 33, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 35. The compound for use according to embodiment 34, wherein about 3 mg of compound 1 is administered to the subject per day. 36. The compound for use according to any one of embodiments 32-35, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 37. A compound having the following formula for use in improving working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 38. The compound for use according to embodiment 37, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered daily to the subject. 39. The compound for use according to embodiment 37 or 38, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 40. The compound for use according to embodiment 39, wherein about 3 mg of compound 1 is administered to the subject per day. 41. The compound for use according to any one of embodiments 37 to 40, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 42. A compound having the following formula for use in improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 43. The compound for use according to embodiment 42, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered daily to the subject. 44. The compound for use according to embodiment 42 or 43, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 45. The compound for use according to embodiment 44, wherein about 3 mg of compound 1 is administered to the subject per day. 46. ​​The compound for use according to any one of embodiments 42-45, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 47. A compound having the following formula for use in improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 48. The compound for use according to embodiment 47, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered daily to the subject. 49. The compound for use according to embodiment 47 or 48, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 50. The compound for use according to embodiment 49, wherein about 3 mg of compound 1 is administered to the subject per day. 51. The compound for use according to any one of embodiments 47 to 50, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 52. The compound for use according to any one of embodiments 27 to 51, wherein the subject is an adult. 53. A compound having the following formula for the preparation of a medicament for treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject: [ka] or a pharma- ceutically acceptable salt thereof. 54. The use according to embodiment 53, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject daily. 55. The use according to embodiment 53 or 54, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 56. The use of embodiment 55, wherein about 3 mg of compound 1 is administered to the subject per day. 57. The use according to any one of embodiments 53 to 56, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 58. A compound having the following formula for the preparation of a medicament for improving executive function in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 59. The use according to embodiment 58, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject daily. 60. The use according to embodiment 58 or 59, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 61. The use of embodiment 60, wherein about 3 mg of compound 1 is administered to the subject per day. 62. The use according to any one of embodiments 58 to 61, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 63. A compound having the following formula for the preparation of a medicament for improving working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 64. The use according to embodiment 63, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject daily. 65. The use according to embodiment 63 or 64, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. 66. The use according to embodiment 65, wherein about 3 mg of compound 1 is administered to the subject per day. 67. The use according to any one of embodiments 63 to 66, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 68. A compound having the following formula for the preparation of a medicament for improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 69. The use according to embodiment 68, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject daily. 70. The use according to embodiment 68 or 69, wherein compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day. 71. The use of embodiment 70, wherein about 3 mg of compound 1 is administered to the subject per day. 72. The use according to any one of embodiments 68 to 71, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 73. A compound having the following formula for the preparation of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease: [ka] or a pharma- ceutically acceptable salt thereof. 74. The use according to embodiment 73, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject daily. 75. The use according to embodiment 73 or 74, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day. 76. The use of embodiment 75, wherein about 3 mg of compound 1 is administered to the subject per day. 77. The use according to any one of embodiments 73 to 76, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally. 78. The use according to any one of embodiments 53 to 77, wherein the subject is an adult.

Claims

1. 1. A method of treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, comprising administering to the subject a compound having the formula: 【Chemistry 18】 or a pharma- ceutically acceptable salt thereof.

2. 1. A method of improving executive function in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the formula: 【Chemistry 19】 or a pharma- ceutically acceptable salt thereof.

3. 1. A method of improving working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the formula: 【Chemistry 20】 or a pharma- ceutically acceptable salt thereof.

4. 1. A method of improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the formula: 【Chemistry 21】 or a pharma- ceutically acceptable salt thereof.

5. 1. A method of improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, comprising administering to the subject a compound having the formula: 【Chemical 22】 or a pharma- ceutically acceptable salt thereof.

6. The method of any one of claims 1 to 5, wherein Compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject daily.

7. The method of any one of claims 1 to 6, wherein Compound 1, or a pharma- ceutically acceptable salt thereof, is administered to the subject at a dose of about 3 mg / day.

8. 8. The method of claim 7, wherein about 3 mg of Compound 1 is administered to the subject per day.

9. The method of any one of claims 1 to 8, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally.

10. 2. For use in treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, a compound having the formula: 【Chemistry 23】 or a pharma- ceutically acceptable salt thereof.

11. 2. For use in improving executive function in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, a compound having the formula: 【Chemistry 24】 or a pharma- ceutically acceptable salt thereof.

12. 2. For use in improving working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, a compound having the formula: 【Chemistry 25】 or a pharma- ceutically acceptable salt thereof.

13. 2. For use in improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, a compound having the formula: 【Chemistry 26】 or a pharma- ceutically acceptable salt thereof.

14. 2. A compound having the formula: 【Chemical 27】 or a pharma- ceutically acceptable salt thereof.

15. The compound for use according to any one of claims 10 to 14, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to said subject daily.

16. The compound for use according to any one of claims 10 to 15, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to said subject at a dose of about 3 mg / day.

17. 17. The compound for use according to claim 16, wherein about 3 mg of compound 1 is administered to the subject per day.

18. The compound for use according to any one of claims 10 to 17, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally.

19. 2. The method of claim 1, wherein the compound is a compound selected from the group consisting of: 【Chemistry 28】 or a pharma- ceutically acceptable salt thereof.

20. For the preparation of a medicament for improving executive function in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, a compound having the formula: 【Chemical 29】 or a pharma- ceutically acceptable salt thereof.

21. 2. For the preparation of a medicament for improving working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, a compound having the formula: 【Chemistry 30】 or a pharma- ceutically acceptable salt thereof.

22. 2. For the preparation of a medicament for improving learning in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, a compound having the formula: 【Chemistry 31】 or a pharma- ceutically acceptable salt thereof.

23. 2. For the preparation of a medicament for improving learning and working memory in a subject with mild cognitive impairment (MCI) associated with Huntington's disease, a compound having the following formula: 【Chemistry 32】 or a pharma- ceutically acceptable salt thereof.

24. The use according to any one of claims 19 to 23, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject daily.

25. The use according to any one of claims 19 to 24, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered to the subject at a dose of about 3 mg / day.

26. 26. The use of claim 25, wherein about 3 mg of compound 1 is administered to the subject per day.

27. The use according to any one of claims 19 to 26, wherein compound 1 or a pharma- ceutically acceptable salt thereof is administered orally.